H-CYTE, Inc.
HCYT
Other OTC1.00
USD
+0.00
- -
CIK
0001591165
ISIN
US4041241096
CUSIP
404124109
Return %
Stock
S&P500
1Y
-72.36
19.01
3Y
-98.52
65.48
5Y
-99.72
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael W. Yurkowsky
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2202 North West Shore Boulevard Tampa FL United States of America 33607
- IPO Date
- Dec 19, 2014
- CIK
- 0001591165
- Website
- hcyte.com
- Similar Companies
- Business
- H-CYTE, Inc. is a medical biosciences company specializing in regenerative medicine and autologous cellular therapies aimed at treating chronic health conditions, primarily chronic respiratory and pulmonary disorders such as chronic obstructive pulmonary disease (COPD). Its core products and services include the DenerveX System, designed to provide long-lasting relief from pain associated with facet joint syndrome; the regenerative tissue product SkinDisc™, which aids wound healing and limb salvage; and the proprietary PRP-PBMC therapy for chronic lung diseases. The company also manages the Centers for Respiratory Health, focusing on cellular therapies and data-driven patient care for pulmonary conditions. Founded in 2013 and headquartered in Tampa, Florida, H-CYTE operates mainly in the United States with a commitment to advancing next-generation cellular therapeutics. Recent major developments include the acquisition of SkinDisc, a patent-pending regenerative tissue technology showing early clinical success with accelerated healing outcomes, with plans for FDA De Novo 510(k) submission. The company completed the acquisition of Jantibody, an immunotherapeutic targeting ovarian cancer and other diseases, aiming for Orphan Drug Designation to secure market exclusivity. H-CYTE also announced a letter of intent to acquire Catheter Precision, Inc., enhancing its portfolio with FDA-approved devices addressing cardiac arrhythmias. To support its strategic shift toward a hybrid biopharmaceutical model, H-CYTE executed significant warrant exercises to raise capital, facilitating expansion into new diagnostics, therapeutics, and medical devices. In mid-2023, the company rebranded to Innoveren Scientific Inc. but continues to develop its diversified portfolio of medical technology and bioscience products. H-CYTE's product pipeline and operational focus combine the manufacture and commercialization of innovative medical devices and regenerative medicine therapies targeting chronic and orphan diseases, emphasizing personalized and data-driven approaches to improve patient outcomes in pulmonology, oncology, cardiology, and chronic pain management.